1001 studies found for:    "Follicular lymphoma"
Show Display Options
Rank Status Study
1 Active, not recruiting Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma
Conditions: Stage II Grade 1 Contiguous Follicular Lymphoma;   Stage II Grade 1 Non-Contiguous Follicular Lymphoma;   Stage II Grade 2 Contiguous Follicular Lymphoma;   Stage II Grade 2 Non-Contiguous Follicular Lymphoma;   Stage II Grade 3 Contiguous Follicular Lymphoma;   Stage II Grade 3 Non-Contiguous Follicular Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Pharmacological Study;   Biological: Rituximab
2 Recruiting Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma
Conditions: Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage II Grade 1 Contiguous Follicular Lymphoma;   Stage II Grade 1 Non-Contiguous Follicular Lymphoma;   Stage II Grade 2 Contiguous Follicular Lymphoma;   Stage II Grade 2 Non-Contiguous Follicular Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Biological: Rituximab;   Radiation: Yttrium Y-90 Ibritumomab Tiuxetan
3 Active, not recruiting Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma
Conditions: Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Refractory Follicular Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis
4 Active, not recruiting Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy
Conditions: Follicular Lymphoma;   Follicular Non-Hodgkin´s Lymphoma;   Autologous Effector Lymphocytes
Intervention: Biological: Autologous effector lymphocytes expanded ex-vivo
5 Completed Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Follicular Lymphoma;   Chronic Lymphocytic Leukemia;   Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular
Intervention: Drug: ofatumumab
6 Active, not recruiting Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma
Conditions: Grade 3a Follicular Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma
Interventions: Drug: Bendamustine Hydrochloride;   Drug: Bortezomib;   Radiation: Fludeoxyglucose F-18;   Other: Laboratory Biomarker Analysis;   Biological: Ofatumumab;   Procedure: Positron Emission Tomography with Radiolabeled Targeting Agent
7 Active, not recruiting Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: Rituximab;   Drug: Lenalidomide;   Drug: Rituximab-CHOP;   Drug: Rituximab-CVP;   Drug: Rituximab-Bendamustine
8 Active, not recruiting
Has Results
Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Conditions: Stage II Grade 1 Contiguous Follicular Lymphoma;   Stage II Grade 1 Non-Contiguous Follicular Lymphoma;   Stage II Grade 2 Contiguous Follicular Lymphoma;   Stage II Grade 2 Non-Contiguous Follicular Lymphoma;   Stage II Grade 3 Contiguous Follicular Lymphoma;   Stage II Grade 3 Non-Contiguous Follicular Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Biological: Rituximab
9 Active, not recruiting Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
Condition: Recurrent Follicular Lymphoma
Interventions: Drug: idelalisib;   Drug: lenalidomide
10 Terminated Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
Conditions: Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma
Interventions: Biological: oblimersen sodium;   Biological: rituximab;   Other: laboratory biomarker analysis
11 Recruiting Idiotypic Vaccination for Follicular Lymphoma Patients
Conditions: Follicular Lymphoma;   First Relapse/Progression
Intervention: Biological: Follicular lymphoma, patient-specific, soluble protein idiotype vaccine
12 Active, not recruiting A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: Rituximab;   Drug: Lenalidomide;   Drug: Rituximab - CHOP;   Drug: Rituximab - CVP;   Drug: Rituximab - Bendamustine
13 Completed Randomized Study for Patients With Follicular Lymphoma Needing Treatment
Condition: Follicular Lymphoma
Interventions: Procedure: CHVP + interferon;   Drug: fludarabine;   Procedure: CHOP + TBI and autotransplant
14 Unknown  Zevalin® First Line in Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: 90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab;   Drug: Rituximab
15 Unknown  Dietary Intervention in Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: Omega 3 fatty acids (EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid));   Drug: Selenium (L-Selenomethionine),;   Drug: Garlic extract (Allicin);   Drug: Pomegranate juice (ellagic acid);   Drug: Grape juice (resveratrol, quercetin);   Drug: Green Tea (Epigallocathechin gallate)
16 Recruiting A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients
Condition: Follicular Lymphoma
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Prednisolone;   Drug: Fludarabine
17 Completed Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma
Condition: Follicular Lymphoma
Intervention: Other: Combination of treatment modalities
18 Recruiting Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab
19 Completed
Has Results
Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma
Condition: Follicular Lymphoma
Intervention: Procedure: Immunochemotherapy, in vivo purging and autrotransplant
20 Recruiting Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Radiation: Radiotherapy;   Biological: Rituximab;   Biological: Autologous dendritic cells;   Biological: GM-CSF;   Biological: Pembrolizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years